TrialTrials2012

Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.

Lena Schiffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.